Disarm Therapeutics has seen a strong $30 million series A round as it looks for a breakthrough approach in axonal degeneration.
Ultragenyx is putting up $138 million in cash to wrestle gene therapy biotech Dimension away from its first suitor.
Lefamulin held its own against established treatment moxifloxacin, raising hopes that Nabriva can establish it as a first-line treatment of CABP.
Rodin has gained $27 million as it plots clinical work on a new Alzheimer’s candidate next year.
In a phase 2 atopic dermatitis trial, Eli Lilly and Incyte's baricitinib hit its primary endpoint but missed a secondary objective.
The data monitoring committee ended the trial after ruling it would be futile to keep treating patients with the BMS-partnered Prostvac.
Sanofi and Lexicon aim to carve out a place for their experimental SGLT2/SGLT1 drug sotagliflozin in Type 1 diabetes.
The ear disease firm is laying off one-third of its noncommercial staff and hitting pause on its remaining pipeline programs.
Moderna looks to take an AstraZeneca-partnered med into phase 2 and start on I-O, while making changes to its venture model.
The agreement positions Bristol-Myers to develop subcutaneous formulations of molecules against PD-1 and 10 other immuno-oncology targets.